Participant information and consent form – Study details

Title	A Phase 1/2, Randomized, Parallel-Arm, Vehicle-Controlled Study to Assess the Ocular Tolerability, Safety, Pharmacodynamics, and Efficacy of NVK029 and Isopto® Carpine (Pilocarpine Hydrochloride) in Presbyopic Emmetropic Participants	
Protocol number	CP-NVK029-0001	
Project sponsor	Nevakar, Inc. (Nevakar)	
Study doctor	Dr Susan Thackwray	
Clinical contact person	Georgina Street	07 5456 3797
24-hour medical contact	000	CTC@usc.edu.au

1. Would you like to take part in this clinical study?

You are being invited to participate in this study because you have a condition called Presbyopia. Presbyopia is a visual condition involving age-related inflexibility of the lens, resulting in inability to focus clearly on near objects.

This document tells you about the study and describes what will happen if you agree to participate. If there is anything you do not understand or want to know more about, please ask us.

Participation in this study is voluntary. If you do not wish to participate you do not have to.

If you do not know what to ask, there are some questions to consider in the *Clinical study participant information and consent form: Part A – General information*.

You might also want to talk to a relative, a friend or your General Practitioner (GP), before you make up your mind. You may also take this form away with you to read carefully at home while you make a decision. If you decide to go ahead, we will ask you to sign the consent form (*the last page of this document*).

2. Why are we doing this research?

This study aims to explore NVK029 as a non-invasive pharmacological treatment for presbyopia. NVK029 is an experimental treatment. This means that it is not an approved treatment for Presbyopia in Australia.

The study will utilise multiple vision tests and eye examinations to fully accomplish study objectives. This includes testing at different light levels and at distances such as may be used for near reading such as reading a book or intermediate such as computer distance.

In this study we are investigating the topical eye drop NVK029. This has the active ingredient of carbachol. Carbachol was previously approved for the treatment of glaucoma however it is currently approved in Australia as an injection for eye lens replacement operations in Australia.

Pilocarpine is approved for use in Australia for the treatment of glaucoma by lowering intraocular pressure. It is not approved for use in the treatment of presbyopia.

Presbyopia is a visual condition involving an age-related inability to focus clearly on near objects. Therapeutic approaches to presbyopia cover a spectrum of non-surgical and surgical techniques. The most common non-invasive method of correcting presbyopia is through the use of bifocal or multifocal lenses. There are currently no Therapeutic Goods Administration (TGA) approved drug products to treat presbyopia.

Presbyopia treatment modalities are based on reducing pupil sizes because smaller pupil sizes increase near visual acuity by increasing focus depth. Research suggests that NVK029 may work as a potential treatment for presbyopia. In a previous study reported in 2016, 3% carbachol had a modest effect on pupil size and on near vision acuity at 1, 2, and 4 hours, though no effect remained at 8 hours. This data supports further testing of carbachol as a potential treatment for presbyopia. Therefore study sponsor, Nevakar, would like to test if this can reduce pupil size and improve near visual acuity, with no significant dimness of vision, loss of distance visual acuity, or other complications.

Your participation will help answer the following questions:

- How effective is NVK029 at improving vision at different distances and brightness?
- Is NVK029 safe or are there side effects?
- How does NVK029 compare to 1% pilocarpine (commercially available in Australia as Isopto® Carpine) and placebo?

3. Do I have to take part?

If you do not wish to take part in the clinical study, you do not t have to. If you decide to take part and later change your mind, you are free to withdraw at any stage. If you choose not to take part, or if you choose to take part and then later withdraw, you will still be able to access your usual medical care. Your choice will not affect your relationship with those treating you, or with this institution.

If you choose not to join the study, the study doctor will discuss other treatment options with you.

We must keep any information we collect about you, up until you withdraw. CNS (the Contract Research Organisation conducting the study) will monitor the information collected to verify it is correct. The sponsor Nevakar, has access to data collected in this study so they can check if the data collected is correct. Nevakar will **not** have access to your name or home address. If you do not agree with this, then we cannot allow you to join the clinical study.

4. What is involved in the study?

Before any study assessments or procedures, you will be asked to sign the consent form.

You may need to have some assessments or medical check done to find if you are suitable.

These include:

- Medical, ocular and social (previous/current use of tobacco/alcohol/drugs of abuse) history.
- You will be asked about any medications, vitamins, supplements, or complementary medicines or supplements that you are taking.
- A complete physical examination will be done. Your overall health will be assessed as well as your head, ears, eyes, nose, throat, mouth (including teeth), thyroid, chest (heart, lungs), abdomen, skin, neurological, extremities i.e. hands and feet, back, neck, musculoskeletal and lymph nodes. You may be asked to lift or remove your clothing to gain access to your chest for examination of heart and lungs. This will be performed behind a closed curtain for your privacy.
- Vital sign measurements (blood pressure, pulse rate, breathing rate and temperature). You will be required to sit for 5 minutes prior to the measurement being taken.

- You will be required to give a urine sample which will be used to perform tests to assess your general health, including screening for drugs of abuse (amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, tetrahydrocannabinols, and Ecstasy (MDMA)). Please note you will not be eligible to participate in this study if you return a positive test result.
- Documentation of your demography (age, gender, race and ethnicity) as part of your medical record will be collected.
- There will be eye examinations performed throughout the study. Some of the eye examinations will require routine eye drops or gentle contact. These are not expected to be painful.

On the day of screening the eye examinations will include:

Vision test to see how well you can read or identify objects (Photopic and Mesopic High Contrast UDVA and UNVA)

You will be asked to read letters/identify objects from a screen as best as you can

These will be done with different settings including close-up vs. distance and bright light vs. darkened

For vision tests measured under darkened conditions you will be required to sit in a dark room for up to 5 minutes each test (Dark Adaption Test).

You will be asked to sit in a completely dark room for 5-10 minutes. A subtle bright light will blink, and you will hit a button when you see that light. Vision Test to see how well your lens can focus without using it's focusing muscles (Cycloplegic Refraction)

This will require some eye drops that will temporarily paralyse the muscles that focus your vision. They may cause a slight temporary stinging that should resolve within a few hours

Your vision may be affected for these few hours and you should not drive until your vision is not affected and you feel driving is safe

Close-up examination of your eye (Slit-lamp examination)

They will have you seated with your head gently resting in a chin-holder of a slit-lamp. This allows the specialist to check your eye for any signs of disease. They may shine bright lights into your eye to see the structures clearly.

Test to see the flow of liquid inside your eye (Gonioscopy)

During the Slit-Lamp Examination the specialist will numb your eyes with eye drops and place a special contact lens with mirrors directly onto your eye

You may feel slight discomfort if the lens contacts other parts of your eye (e.g. eyelashes/eyelid) but this should not be painful and the discomfort will not last beyond one minute

Close-up examination of the back of your eye (Dilated fundus examination)

The specialist will place some eye-drops in that will dilate your pupil to allow them to have a good look at the back of your eye

They may have your chin resting so that a machine can take photos of the back of your eye or they may look with a handheld device from a few inches away

The drops will make objects appear brighter as more light get into your eyes – this will resolve after a few hours

Check of the pressure inside your eyes (Tonometry)

This will be performed by gently blowing air at your eye, gently tapping your eye with a sterile bud – these should not be painful and will not require any drops

Sometimes the specialist may gently place a pressure sensor across your eye – they will provide numbing eye drops to make sure it is not uncomfortable if this occurs

Check of your vision with temporary paralysis of the muscle inside your eye (Cycloplegic refraction)

Before each dose and at time intervals after each dose the eye examinations will include:

Certain vision tests measured at Screening (see exception and explanation below)

These will be at differing distances and levels of light brightness

They will not be including the tests involving paralysis of the eye muscles (Cycloplegic Refraction)

In addition, there will be tests to measure reading speed at low lights (Mesopic high-contrast uncorrected reading speed)

The eye pressure checks (tonometry)

The close-up examination of your eye (Slit-Lamp Examination)

Excluding the test for the flow of liquid in your eye (Gonioscopy)

Excluding the examination of the back of your eye after pupil dilation (Dilated Fundus Examination)

A test of how well your eyes can focus on near objects (Amplitude of Accommodation)

Your chin will be resting in a machine (Autorefractor) and you will be asked to focus on objects that appear close

Measure of the diameter of your pupils in low light (Mesopic Pupil diameter)

Using a hand-held sensor that may be gently in place against your forehead or the bony part of your face around your eye – this should take a few seconds and not contact your eye

The eye tests will be conducted before dosing and as frequently at 0.5, 1, 2, 3, 4 and 8 hours after the eye dosing of the experimental medication. The close-up eye examination (Slit-Lamp) will occur before dosing and 8 hours after.

The eye pressure tests will take place before dosing and 3 hours after.

Participation in the study will be 3 visits over 8 days. 1 Screening visit 1-14 days before this will occur.

During this 8-hour period you will be required to be under the supervision of the study staff. Food and beverages will be provided as well as facilities to wait between assessments.

These activities are summarised in the Schedule of Assessments.

The study staff will discuss requirements for participation in this study. It is important to be open and honest about your medical history.

To take part in this study you must be:

- 40-60 years old
- In good general health
- Have poor vision at near sight
- Not be pregnant nor lactating
- Be able and willing to attend the visits
- Qualify for presbyopia on testing
- Be willing to use highly effective contraception during the study

Women

You must use highly effective methods of contraception/birth control (methods which result in low failure rate, i.e. less than 1% per year, when used consistently and correctly).

Examples of acceptable forms of contraception in this study include:

- established use of oral, injected or implanted hormonal methods of contraception
- placement of an intrauterine device (IUD) or intrauterine system (IUS)
- surgical sterilisation at least 6 months prior to screening such as tubal occlusion, hysterectomy, bilateral salpingectomy or bilateral oophorectomy
- sterilised male partner (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate) at least 6 months prior to screening
- true abstinence: When this is in line with your preferred and usual lifestyle.
- Condoms

Examples of non-acceptable methods of contraception include:

- periodic abstinence (e.g. calendar, ovulation, symptothermal, post ovulation)
- withdrawal
- spermicide (as it is not approved as a method of contraception in Australia).

If you are uncertain of what form of contraception is acceptable for use during the study, then please ask your study doctor.

Men

It is highly recommended that you inform your partner of your participation in the study and that highly effective methods of contraception (as detailed above) are strongly recommended.

Further, you must agree that if your partner becomes pregnant while you are on the study, you will advise the study doctor who will then provide you with an authorisation form to present to your partner. If she agrees, that authorisation will function as consent to approve the study doctor's access to medical information to allow monitoring of the pregnancy, and the birth and the health of the child at birth.

You cannot take part in this study if:

- You have eye disease that may significantly affect your safety whilst on the study or impact the research testing – including corneal abnormalities, dry eye disease, intraocular hypotension, intraocular hypertension, intraocular surgery
- You use punctal plugs (tear duct plugs)
- Have an allergy to carbachol or the substances the treatments include
- Have preplanned surgery during the study
- During the study period you must not:
- Become pregnant or impregnate your partner
- Donate sperm for >90 days after the last dose of drug
- Participate in any other investigational therapy
- Use contact lenses
- Use illicit drugs
- Drink more than 2 alcoholic beverages per day
- Take any cholinergic, anticholinergic drugs or antihistamines

We will assign you to one of four groups of participants on a 'chance' basis: like flipping a coin.'

You will have a one in four chance of being given one of the following treatments:

- NVK029 (Carbachol 0.75%)
- NVK029 (Carbachol 3%)
- Placebo
- Isopto® Carpine (Pilocarpine Hydrochloride) 1%

The placebo is a substance that does not contain an active ingredient. It will appear the same as the medication but have no clinical effect. Using a placebo helps give confidence that the effects measured in other groups are due to the active drug.

To avoid accidentally influencing tests, neither you nor the researches will know whether you received the placebo or a dose of NVK029. If it is necessary for your care however, we can find out what you have been given.

5. Schedule of Assessments

	Screening	**Randomisation and Dosing**		**Dosing**	**End Of Study**	
	Visit 1	**Visit 2**		**-**	**Visit 3**	
	Day -14 to Day -1	**Day 1**		**Day 2 ~ Day 7**	**Day 8**	
Assessment		Pre	Post		Pre	Post
Informed Consent	X					
Medical and Medication history, Study suitability, Demographics	X					
Randomisation		X				
Vital signs	X	X	X		X	X

	Screening	Randomisation and Dosing		Dosing	End Of Study	
	Visit 1	Visit 2		-	Visit 3	
Assessment	Day -14 to Day -1	Day 1		Day 2 ~ Day 7	Day 8	
		Pre	Post		Pre	Post
Physical Exam	X	X			X	
Urine drug screen	X					
Urine pregnancy test	X				X	
Dark adaptation for approx.. 5-10minutes	X	X	X		X	X
Low light intermediate vision test		X	X		X	X
Low light near vision test	X	X	X		X	X
Low light reading speed		X	X		X	X
Bright light distance vision test	X	X	X		X	X
Vision test with temporary paralysis of the muscle inside your eye	X					
Close up Examination of the eye	X	X	X		X	X
Test of pressure in eye	X	X	X		X	X
Test of flow of liquid in the eye	X					
Examination of the back of the eye with the pupil dilated	X					
Study drug administration		X		X (self-administration, at 8 am)	X	
Test of how well the eye focuses on near objects		X	X		X	X
Assessment of eye redness		X				X
Pupil size in Low light		X	X		X	X
Participant-reported outcome (NEI VFQ-25 modified near vision subscale) questionnaire	X	X			X	
Participant-reported Vision Side Effect and Headache/Brow Arch questionnaire		X	X		X	X
Issue diary card			X			
Collect diary card					X	
Medications check			X	X		X
Adverse Events check	X		X	X		X

During Visits 2 and 3 (one week after visit 2) you will be required to have some of the ophthalmologic assessments listed above completed at 0.5, 1, 2, 3, 4, and 8 hours after administering the eye drops. You will be required to be at the study centre for the completion of the assessments. It is estimated that the screening visit will take up to 3 hours and the subsequent visits at Day 1 and Day 8 will take up to 10 hours.

The described tests are performed to further our knowledge about how the study medication works and it may not produce the type of results that will have any useful meaning that would affect your health or treatment. Therefore, you may or may not be informed of the results of the tests.

Pregnancy

The effect of the study medication on your fertility, including future fertility, may not be known.

The effects of the study medication on the unborn child and on the new-born baby are not known. Because of this, participants must not participate in the research if pregnant, trying to become pregnant, breastfeeding, or planning ovum donation.

If you are female and childbearing is a possibility, you will be required to undergo a pregnancy test prior to commencing the research project. If you are male, you should not father a child or donate sperm for at least 90 days after the last dose of study drug.

Both male and female participants must avoid pregnancy during the course of the study, and for a period of 1 week after completion of the research project, as there is potential risk for an abnormal child being born. It is highly recommended that you inform your partner of your participation in the study and the need to avoid pregnancy. The study doctor must discuss effective methods of avoiding pregnancy with you.

For female participants, if you do become pregnant whilst participating in the research project, you should advise your study doctor immediately. Your study doctor will withdraw you from the study and advise on further medical attention should this be necessary. You must not continue in the study if you become pregnant. In the event you do become pregnant during the dosing period or within 48 hours of the last dose, the sponsor will request that you sign a separate consent form to allow monitoring of your pregnancy, the birth and the health of your child at birth.

For male participants, you should advise your study doctor if you father a child while participating in the study. Your study doctor will advise on medical attention for your partner should this be necessary.

You should discuss with your study doctor effective methods of avoiding this. It is recommended that a condom be worn for all sexual intercourse.

6. Who is conducting and paying for this research?

All treatment, medication and study-related tests will be provided at no cost to you.

This research is being conducted by Nevakar, Inc. (Nevakar) based in the United States. The Clinical Research Organisation involved in monitoring the study and acting as the local sponsor is Clinical Network Services (CNS) Pty Ltd.

Nevakar may benefit financially from this research study if, for example, the study assists with obtaining approval for a new drug.

By taking part in this research study you agree that data generated from analysis of your tests may be provided to Nevakar.

Nevakar may directly or indirectly benefit financially from your test results or from knowledge acquired through analysis of your data collected.

If knowledge acquired through this research leads to discoveries that are of commercial value to Nevakar the study doctors or their institutions, there will be no financial benefit to you or your family from these discoveries.

Nevakar other researchers, or research companies may patent or sell discoveries that result from this research. Neither Nevakar nor the study doctor will compensate you if this happens.

Contractors engaged by Nevakar will receive a payment from Nevakar for undertaking this research study.

No member of the research team will receive a personal financial benefit from your involvement in this research study (other than their ordinary wages).

7. What if something new comes up during the study?

If we find something new about an intervention while the study is under way, the study doctor will discuss with you what it means and whether you want to continue in the study. If you decide to continue in the clinical study, we will ask you to sign an updated consent form.

8. What will happen to the confidential information about me?

We will keep all personal information confidential and securely stored.

All of the collected data will be coded. No personal information about you, such as your name and address will leave the clinic, and all study information sent out from the clinic you will be identified with a code number only.

9. What information will be collected, and how will it be stored?

Australian and Queensland privacy law gives you the right to request access to your information that the researchers have collected and stored. The law also gives you the right to request corrections to any information about you that you disagree with. Please contact the study team on page 14 of this document if you would like to access your information.

We will not disclose your information without your permission, except in compliance with the law. Information about you may be obtained from your health records held at this institution and may be obtained from other health services for the purposes of research. Should you wish to cease treatment we would like the option to maintain follow up. If you sign the consent form, you agree to the study team accessing health records if they are relevant to your participation in this study.

Data will be held on file by the Sponsor, this data may be viewed by staff including the study monitor, external auditors on behalf of the Sponsor and the appropriate regulatory authorities. A study report will be prepared and may be submitted to regulatory authorities for publication. However, you will be identified in all reports by the study identification number, gender and age. Your data will be held in strict confidence.

All source data, clinical records and laboratory data relating to the study will be archived for 15 years after the completion of the study. All data will be available for retrospective review or audit.

After 15 years, the study records could either be transferred to the Sponsor or destroyed with documented authorization from the Sponsor. If it is transferred to the sponsor, the re-identifiable/coded information, which contains confidential information identifying the study subjects, will be provided to the sponsor in a sealed envelope labelled "confidential". If study records will be destroyed, documentation of destruction will be provided to the Sponsor. No study records will be destroyed without prior written agreement between the Sponsor and the Investigator. If the Investigator wishes to assign the study records to another party or move them to another location, the Investigator must notify the Sponsor in writing of the new responsible person and/or the new location.

Any information and data obtained/retained in connection with this research study that can identify you will remain confidential and will only be used for the purpose of this research study.

Information about you may be obtained from your health records held at other health services for the purpose of this research. By signing the consent form you agree to the study team, including Sponsor delegates, accessing health records if they are relevant to your participation in this research study to ensure data accuracy. Whilst every effort will be made to keep your personal information confidential, the data gathered for this study will also be reviewed by a Sponsor delegate. This delegate will have access to your medical records, without violating your confidentiality to the extent permitted by local laws and regulations, to verify the data are correct and complete.

The data collected as part of this research study may be reviewed by representatives of the international sponsor, Nevakar, Inc, its affiliated companies and/or subcontractors, the local sponsor, Clinical Network Services (CNS) Pty Ltd, the Research Ethics Committee of Bellberry HREC, by authorised representatives of the Australian Therapeutic Goods Administration or other regulatory agencies. Information may be transferred to parties in countries (and regions) other than Australia including the US, and Europe for these purposes, where regulations and laws relating to data protection may not be as extensive as in Australia. Clinical Network Services (CNS) Pty Ltd, Nevakar, Inc representatives, collaborators and contracted agencies comply with internal procedures to protect personal information even in countries whose data privacy laws are less strict than those of this country. In all cases when dealing with your personal (coded) information. Nevakar, Inc, and any of their agents will comply with the Privacy Act 1988. If you have any concerns on how your information is handled, please feel free to ask a member of the study team for more information.

By signing the consent section, you authorise release of, or access to, this confidential information to the relevant study personnel and regulatory authorities as noted above.

10. What are my responsibilities during the study?

If you agree to participate in this study, you agree to be responsible for using the eye drops according to the instructions given to you by study staff. You will be asked to avoid night-time driving during the study period if you believe your vision at night is dim, dark or blurred, or limited in any way, and avoid operating machinery if you feel your vision is negatively affected as these drops affect pupil reduction and may make vision in the dark more difficult. The use of reading glasses should be limited or avoided as much as possible from the entry into the study until the completion of the study on Day 8.

You will be unable to use contact lenses one month prior to commencing the study, during the study and three months after completing the study.

You will be asked to limit your alcohol consumption to approximately 2 alcoholic beverages per day during the 30-day study period

You agree to inform the study doctor and study staff of changes to your medications or medical history during the study.

You also agree to comply with the other conditions in this document. If you cannot, or do not wish to accept this responsibility, then you will not be able to participate in the study.

11. Can I have other medicines or procedures during this clinical study?

The following medications are prohibited while on the study as they can influence the effect of the test medications

- Other cholinergic drugs besides the test medications. These can come in many forms including oral and eye drops
- Anti-cholinergic drugs – these can come in many forms including oral and eye drops
- Antihistamines – these can come in many forms including oral, on the skin and eye drops

As there are many different medications that can be included – the study doctor will check your current list of medications. If you are to start a new medication, please inform the study doctor as soon as possible so they may advise if it is included.

12. What possible benefits might I get by taking part?

We cannot promise you any personal benefits from this research.

By taking part, you may contribute to research and be helping other people in the future

13. What risks do I run by taking part?

Medical procedures, medicine and tests often have side effects. You may have no side effects, some or all of the side effects listed below. These side effects may be mild, moderate or severe. If you have any of these side effects, or are worried about them, talk with your study doctor. Your study doctor will also be looking out for side effects.

This is the first time NVK029 will be administered in humans. It is anticipated that approximately 38 participants will take part in this study at this site. However, the active ingredient, carbachol, has reported the following side effects.

Common side effects (3-10%) included: Temporary headaches and mild burning sensations.

Other risks for NVK029 include temporary:

- Eye redness
- Reduced/blurred vision
- Eye irritation
- Drooling
- Fainting or feeling faint
- Atypical heart rhythms
- Stomach cramps, Diarrhoea
- Nausea/Vomiting
- Low blood pressure
- Urinary frequency
- Increased sweating
- Retinal detachment

Risks for Pilocarpine use include temporary:

- Headache
- Difficulty focusing
- Blurred vision
- Eye irritation

- Eye pain

- Retinal detachment

Both medications may increase the risk of retinal detachment which will require surgery to correct if it occurs. Your study doctor can provide further information on this risk and procedure.

Both medications may make driving in the dark riskier as low light vision may be affected,

There may also be side effects that the researchers do not expect or do not know about and that may be serious. Tell your study doctor immediately about any new or unusual symptoms that you get.

Many side effects go away shortly after the intervention ends. However, sometimes side effects can be serious, long lasting or permanent. If a severe side effect or reaction occurs, your study doctor may need to stop your procedure. Your study doctor will discuss the best way of managing any side effects with you. Some unwanted effects may actually not be related to the study, nevertheless it is important to document these.

12. How will you use any tissues or samples you take from me?

We will not collect any tissues or samples from you in this study.

Will you be doing any genetic tests?

There are no genetic tests in this study.

13. What happens if I suffer severe side effects as a result of my participation in this study?

If you suffer any complications or side effects as a result of using the study medication, please contact us as soon as possible. In case of an emergency, contact 000.

14. Will you pay me to participate in this study?

If accepted into the study, as payment for your time, out of pocket expenses and inconvenience experienced you will receive $1300 for completing the study. If you have completed all screening procedures including the eye evaluations and excluded from the study, you will receive $300. This payment is not made for undergoing risk, nor is it to compensate you for any loss of earnings as a result of your participation in the study. By participating in the study, there will be no costs payable by you. Meal/beverage vouchers will be provided during the Day 1 and Day 8 visits. The cost of travel can either be met through reimbursement of petrol costs or provision of taxi vouchers. If the study is terminated by the Sponsor or the Principal Investigator prior to completion, or if you decide to withdraw or the Principal Investigator decides to withdraw you from the study for any reason before completion, then a pro-rata payment will be made.

If you choose to withdraw your consent to participate in the study, the study centre staff will assess the level of payment, to which you are entitled. This amount will be calculated in relation to which study visits/procedures you complete. You should also be aware that your study payment may be reduced or forfeited if you fail to comply with any of the study requirements. The level of pro-rata payment to which you are entitled if you are withdrawn from the study due to medical or non-medical reasons, and any penalties incurred will be at the discretion of the investigator after consultation with relevant study centre staff.

Any payment received may be considered taxable income. Participants are encouraged to seek independent financial advice as to how any payment may affect your personal financial situation.
Your participation in this study may be stopped at any time by the Principal Investigator or the Sponsor without your consent. Should this occur, you will receive a fair portion of the full payment based which study visits/procedures you complete. The anticipated circumstances under which this might occur should be included (e.g. failure to take study medications as prescribed or missing scheduled study visits). This may be for reasons of your safety or if you are not complying with the study restrictions as outlined to you. If you are withdrawn from the study due to an adverse reaction, then you may receive the full payment amount. The Sponsor may decide at any time to stop the study, in which case you would be withdrawn.

15. What happens when the study ends?

The experimental drug will not be available to you following completion of participation. The study data will be analysed, and a final report provided to the study doctor, who will share the results with you when requested. The disclosure and/or any published results will be available to you when requested. It is usual for a number of years to elapse before definitive results of this type of study are available. These may be published in medical journals that are available to the public. You should feel free to ask the study staff about this.

16. Could the researchers stop the study early?

Your participation in the study can be stopped without your consent. This could be by the study doctor or the sponsors. Reasons for this include new information about the drug's safety or effectiveness. If the study is stopped early, the study doctor will let you know and explain the reason behind the decision.

The study doctor will discuss with you any medical issues regarding the early stopping of the study.

17. Will the results of the study be published?

A final report will be provided to the Principal Investigators who will be able to share the results with participants when requested.

It is usually a number of months before final results of a study will be available after it ends.

Published results will be available to all participants when requested. These results may be published in medical journals available to the public. These results will be anonymised and grouped – so no specific individual participants will have their information identified.

18. Who do I contact if I have a question or complaint?

If you experience any side effects or complications as a result of this clinical study, you should contact the study team as soon as possible. They will arrange appropriate medical help. 24-hour medical emergency is available by contacting 000 or going to your nearest hospital.

We have included several contacts for you below. Who you contact depends on what information you need.

For all study enquiries or if you want to talk to the study team at any time:

Clinical contact person

Name	Georgina Street
Position	Clinical Operations Manager
Telephone	07 5456 3797
Email	CTC@usc.edu.au

For matters relating to research at the site at which you are participating, the details of the local site complaints person are:

Complaints contact person

Name	Office of the Chief Operating Officer
Address	University of the Sunshine Coast, Sippy Downs QLD 4556
Telephone	07 5456 4789

If you have any further questions regarding this study, please do not hesitate to contact Dr Susan Thackwray on 07 5456 3797.

The Bellberry Human Research Ethics Committee has reviewed this study in accordance with the National Statement on Ethical Conduct in Human Research (2007) incorporating all updates. Should you wish to discuss the study or view a copy of the Complaint procedure with someone not directly involved, particularly in relation to matters concerning policies, information or complaints about the conduct of the study or your rights as a participant, you may contact you may contact the Operations Manager, Bellberry Limited on 08 8361 3222.

All study participants must be provided with a signed and dated copy of the Participant Information Sheet and Consent Form for their personal records

19. What do I do if I need to seek compensation for injury?

• The pharmaceutical industry has set up a compensation process, with which the Sponsor, Clinical Network Services (CNS) Pty Ltd, of this trial has agreed to comply. Details of the process and conditions are set out in the *Medicines Australia Guidelines for Compensation for Injury Resulting from Participation in a Company-Sponsored Clinical Trial*. In accordance with these Guidelines, the sponsor will determine whether to pay compensation to you, and, if so, how much. A copy of the Guidelines is available to you from the research staff on request. If you have any questions about the Guidelines, please contact the complaints contact person listed above.

• You may be able to seek compensation through the courts.

• It is the recommendation of the independent ethics committee responsible for the review of this trial that you seek independent legal advice before taking any steps towards compensation for injury.

20. Insurance

All study doctors are required to have insurance.

21. The Consent Form

Sign the consent form only after you have made up your mind to take part in this clinical study. If you wish, we will arrange for someone to read the form to you in a language you understand. You must be provided with a signed and dated copy of the participant information and consent form for your personal record.

Consent form

Title	**A Phase 1/2, Randomized, Parallel-Arm, Vehicle-Controlled Study to Assess the Ocular Tolerability, Safety, Pharmacodynamics, and Efficacy of NVK029 and Isopto® Carpine (Pilocarpine Hydrochloride) in Presbyopic Emmetropic Participants**	
Protocol number	CP-NVK029-0001	
Project sponsor	Nevakar, Inc	
Study doctor	Dr Susan Thackwray	
Clinical contact person	Georgina Street	07 5456 3797
24-hour medical contact	000	CTC@usc.edu.au

Note: All parties signing the consent section must date their own signature.

22. Declaration by participant

I have read, or have had read to me, and I understand the participant information and consent form.

I am between 40 and 60 (inclusive) years of age.

I understand that my involvement in this study may not be of direct benefit to me.

I have had the opportunity to discuss this with an independent person.

I have had an opportunity to ask questions and I am satisfied with the answers I have received.

I freely agree to participate in this clinical study as described and understand that I am free to withdraw at any time during the study without affecting my future health care.

I understand the purposes, procedures and risks of the research described in the information sheet.

I give permission for my doctors, other health professionals, hospitals, laboratories or ambulances outside this hospital to release information to USC Clinical Trials Centre concerning my medical history, disease and treatment for the purposes of this study. I understand that such information will remain confidential.

I consent to my treating doctor/s being notified of my participation in this study and any clinically relevant information noted by the study doctor in the conduct of the study.

I understand that I will be given a signed copy of this document to keep.

Signature _____ Date_____

Name of participant (please print) _____

23. Declaration by study doctor/senior researcher†

I have given a verbal explanation of the clinical study, its procedures and risks and I believe that the participant has understood that explanation.

Signature _____ Date_____

Name of study doctor/researcher[†] (please print) _____

[†] A senior member of the study team must provide the explanation of, and information concerning, the clinical study.

This page is the manifestation of an electronic signature certifying that I have reviewed the electronic copy of this document and certify that it is an exact copy having all of the same attributes and information as the original document.

Document Name: ICF CP-NVK029-0001_SS PICF Version 1.0 dated 11Jun2020__clean - Version V1.0
Document ID: 12093
No. Pages: 17
Study: Nevakar Inc. - Presbyopia Ph1/2 (Nevakar x CNS) - CP-NVK029-0001

Electronic Signature for: Fiona Groom
Electronically Signed by: fgroom
Date & Time: 17/JUL/2020 1:15 PM AEST
IP Address: 203.29.104.10